Hostname: page-component-6bf8c574d5-2jptb Total loading time: 0 Render date: 2025-02-27T10:20:34.927Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-effectiveness of transdiagnostic group cognitive behavioural therapy for anxiety disorders v. treatment as usual: economic evaluation of a pragmatic randomized controlled trial over an 8-month time horizon using self-reported data

Published online by Cambridge University Press:  25 January 2023

Alexandra Chapdelaine Open the ORCID record for Alexandra Chapdelaine [Opens in a new window] ,
Helen-Maria Vasiliadis Open the ORCID record for Helen-Maria Vasiliadis [Opens in a new window] ,
Martin D. Provencher Open the ORCID record for Martin D. Provencher [Opens in a new window] ,
Peter J. Norton Open the ORCID record for Peter J. Norton [Opens in a new window]  and
Pasquale Roberge Open the ORCID record for Pasquale Roberge [Opens in a new window]
Alexandra Chapdelaine
Affiliation:
PRIMUS Research Group, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, local Z7-3004, Sherbrooke, Québec, J1H 5N4, Canada
Helen-Maria Vasiliadis
Affiliation:
Université de Sherbrooke – Campus de Longueuil, Charles-Le Moyne Research Center, 150 Place Charles Lemoyne, Longueuil, Québec, J4K 0A8, Canada
Martin D. Provencher
Affiliation:
École de psychologie, Pavillon Félix-Antoine-Savard, 2325, rue des Bibliothèques, Université Laval, Québec, Québec, G1V 0A6, Canada
Peter J. Norton
Affiliation:
The Cairnmillar Institute, 391-393 Tooronga Rd, Hawthorn East, Victoria 3123, Australia
Pasquale Roberge*
Affiliation:
Department of family medicine and emergency medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, local Z7-3004, Sherbrooke, Québec, J1H 5N4, Canada
*
Author for correspondence: Pasquale Roberge, E-mail: Pasquale.Roberge@usherbrooke.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

This economic evaluation supplements a pragmatic randomized controlled trial conducted in community care settings, which showed superior improvement in the symptoms of adults with anxiety disorders who received 12 sessions of transdiagnostic cognitive-behavioural group therapy in addition to treatment as usual (tCBT + TAU) compared to TAU alone.

Methods

This study evaluates the cost-utility and cost-effectiveness of tCBT + TAU over an 8-month time horizon. For the reference case, quality-adjusted life years (QALYs) obtained using the EQ-5D-5L, and the health system perspective were chosen. Alternatively, anxiety-free days (AFDs), derived from the Beck Anxiety Inventory, and the limited societal perspective were considered. Unadjusted incremental cost-effectiveness/utility ratios were calculated. Net-benefit regressions were done for a willingness-to-pay (WTP) thresholds range to build cost-effectiveness acceptability curves (CEAC). Sensitivity analyses were included.

Results

Compared to TAU (n = 114), tCBT + TAU (n = 117) generated additional QALYs, AFDs, and higher mental health care costs from the health system perspective. From the health system and the limited societal perspectives, at a WTP of Can$ 50 000/QALY, the CEACs showed that the probability of tCBT + TAU v. TAU being cost-effective was 97 and 89%. Promising cost-effectiveness results using AFDs are also presented. The participation of therapists from the public health sector could increase cost-effectiveness.

Conclusions

From the limited societal and health system perspectives, this first economic evaluation of tCBT shows favourable cost-effectiveness results at a WTP threshold of Can$ 50 000/QALY. Future research is needed to replicate findings in longer follow-up studies and different health system contexts to better inform decision-makers for a full-scale implementation.

Keywords

Anxiety disorderscognitive behaviour therapygroup psychotherapyhealth care economicstransdiagnostic
Type
Original Article
Information
Psychological Medicine , Volume 53 , Issue 14 , October 2023 , pp. 6570 - 6582
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

AlHeresh, R., LaValley, M. P., Coster, W., & Keysor, J. J. (2017). Construct validity and scoring methods of the World Health Organization: Health and work performance questionnaire among workers with arthritis and rheumatological conditions. Journal of Occupational and Environmental Medicine, 59(6), e112–e118. https://doi.org/10.1097/JOM.0000000000001044CrossRefGoogle ScholarPubMed
Altman, D. G., & Bland, J. M. (1995). Absence of evidence is not evidence of absence. BMJ: British Medical Journal, 311(7003), 485. https://doi.org/10.1136/BMJ.311.7003.485CrossRefGoogle Scholar
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.Google Scholar
Andersen, P., Toner, P., Bland, M., & McMillan, D. (2016). Effectiveness of transdiagnostic cognitive behaviour therapy for anxiety and depression in adults: A systematic review and meta-analysis. Behavioural and Cognitive Psychotherapy, 44(6), 673–690. https://doi.org/10.1017/S1352465816000229CrossRefGoogle ScholarPubMed
Balijepalli, C., Gullapalli, L., Druyts, E., Yan, K., Desai, K., Barakat, S., & Locklin, J. (2020). Can standard health technology assessment approaches help guide the price of orphan drugs in Canada? A review of submissions to the Canadian agency for drugs and technologies in health common drug review. ClinicoEconomics and Outcomes Research: CEOR, 12, 445. https://doi.org/10.2147/CEOR.S264589CrossRefGoogle Scholar
Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience, 17(3), 327–335. https://doi.org/10.1016/j.siny.2015.10.004CrossRefGoogle ScholarPubMed
Barlow, D. H., Allen, L. B., & Choate, M. L. (2016). Toward a unified treatment for emotional disorders – republished article. Behavior Therapy, 47(6), 838–853. https://doi.org/10.1016/j.beth.2016.11.005CrossRefGoogle Scholar
Bartram, M. (2017). Making the most of the federal investment of $5 billion for mental health. Canadian Medical Association Journal, 189(44), E1360–E1363. https://doi.org/10.1503/cmaj.170738CrossRefGoogle ScholarPubMed
Beck, A. T., & Steer, R. A. (1993). Beck anxiety inventory manual. San Antonio, TX: Psychological Corporation.Google Scholar
Bekhuis, E., Boschloo, L., Rosmalen, J. G. M., & Schoevers, R. A. (2015). Differential associations of specific depressive and anxiety disorders with somatic symptoms. Journal of Psychosomatic Research, 78(2), 116–122. https://doi.org/10.1016/j.jpsychores.2014.11.007CrossRefGoogle ScholarPubMed
Brazier, J. E., Ara, R., Rowen, D., & Chevrou-Severac, H. (2017). A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics, 35(Suppl 1), S21–S31. https://doi.org/10.1007/S40273-017-0545-XCrossRefGoogle ScholarPubMed
Brazier, J. E., Connell, J., & O'Cathain, A. (2014a). Do EQ-5D and SF-6D ask the right questions in mental health? A content validation using interviews with patients. Value in Health, 17(3), A194. https://doi.org/10.1016/j.jval.2014.03.1133CrossRefGoogle Scholar
Brazier, J. E., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., … Parry, G. (2014b). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures.. Health Technology Assessment, 18(34). https://doi.org/10.3310/hta18340CrossRefGoogle ScholarPubMed
Brazier, J. E., Rowen, D., Lloyd, A., & Karimi, M. (2019). Future directions in valuing benefits for estimating QALYs: Is time up for the EQ-5D? Value in Health, 22(1), 62–68. https://doi.org/10.1016/j.jval.2018.12.001CrossRefGoogle ScholarPubMed
Brettschneider, C., Gensichen, J., Hiller, T. S., Breitbart, J., Schumacher, U., Lukaschek, K., … König, H.-H. (2020). Cost-effectiveness of practice team-supported exposure training for panic disorder and agoraphobia in primary care: A cluster-randomized trial. Journal of General Internal Medicine, 35(4), 1120–1126. https://doi.org/10.1007/s11606-020-05658-9CrossRefGoogle ScholarPubMed
Briggs, A. H. (2000). Economic evaluation and clinical trials: Size matters. British Medical Journal, 321, 1383–1389. https://doi.org/10.1136/bmj.321.7273.1362CrossRefGoogle ScholarPubMed
Brown, T. A., & Barlow, D. H. (2014). Anxiety and related disorders interview schedule for DSM-5 - adult and lifetime version: Clinician manual. New York, NY: Oxford University Press.Google Scholar
Canadian Agency for Drugs and Technologies in Health (2017). Guidelines for the economic evaluation of health technologies (4th ed). Ottawa, Canada: CADTH.Google Scholar
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Filip, Smit., Cuijpers, P., & Saxena, S. (2016). Scaling-up treatment of depression and anxiety: A global return on investment analysis. The Lancet. Psychiatry, 3, 415–424. https://doi.org/10.1016/S2215-0366(16)30024-4CrossRefGoogle ScholarPubMed
Clark, D. A. (2009). Cognitive behavioral therapy for anxiety and depression: Possibilities and limitations of a transdiagnostic perspective. Cognitive Behaviour Therapy, 38(sup1), 29–34. https://doi.org/10.1080/16506070902980745CrossRefGoogle ScholarPubMed
Coalition of Ontario Psychiatrists. (2018). HELP WANTED – Ontario needs psychiatrists. Retrieved from: https://eopa.ca/sites/default/uploads/files/Ontario%20Needs%20Psychiatrists%20FINAL%20-%20August%207%2C%202018.pdfGoogle Scholar
Commission des normes de l’équité de la santé et de la sécurité du travail. (2017). Historique du salaire minimum. Retrieved August 17, 2020, from https://www.cnt.gouv.qc.ca/salaire-paie-et-travail/salaire/historique-du-salaire-minimum/Google Scholar
Connell, J., Brazier, J. E., O'Cathain, A., Lloyd-Jones, M., & Paisley, S. (2012). Quality of life of people with mental health problems: A synthesis of qualitative research. Health and Quality of Life Outcomes, 10, 138. https://doi.org/10.1186/1477-7525-10-138CrossRefGoogle ScholarPubMed
Davis, A., Smith, T., Talbot, J., Eldridge, C., & Betts, D. (2020). Predicting patient engagement in IAPT services: A statistical analysis of electronic health records. Evidence-Based Mental Health, 23, 8–14. https://doi.org/10.1136/ebmental-2019-300133CrossRefGoogle Scholar
Egger, N., Konnopka, A., Beutel, M. E., Herpertz, S., Hiller, W., Hoyer, J., … König, H. H. (2015). Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: Results from the SOPHO-NET trial. Journal of Affective Disorders, 180, 21–28. https://doi.org/j.jad.2015.03.037CrossRefGoogle ScholarPubMed
Egger, N., Konnopka, A., Beutel, M. E., Herpertz, S., Hiller, W., Hoyer, J., … König, H. H. (2016). Long-term cost-effectiveness of cognitive behavioral therapy versus psychodynamic therapy in social anxiety disorder. Depression and Anxiety, 33(12), 1114–1122. https://doi.org/10.1002/da.22540CrossRefGoogle ScholarPubMed
EuroQol Research Foundation. (2019). EQ-5D-5L User Guide v3.0. Retrieved from https://euroqol.org/publications/user-guidesGoogle Scholar
Fleury, M.-J., & Grenier, G. (2012). État de la situation sur la santé mentale au Québec et réponse du système de santé et de services sociaux [The state of mental health in Quebec and the response of the health and social services system]. Québec, Canada: Gouvernement du Québec. Retrieved from Gouvernement du Québec website https://www.csbe.gouv.qc.ca/fileadmin/www/2012/SanteMentale/CSBE_EtatSituation_SanteMentale_2012.pdfGoogle Scholar
Franklin, M., Enrique, A., Palacios, J., & Richards, D. (2021). Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: Construct validity and responsiveness. Quality of Life Research, 30(9), 2633. https://doi.org/10.1007/S11136-021-02833-1CrossRefGoogle ScholarPubMed
Frick, K., Neissen, L., Bridges, J., Walker, D., Wilson, R. F., & Bass, E. B. (2012). Usefulness of Economic Evaluation Data in Systematic Reviews of Evidence. In Report No.: 12(13)-EHC114-EF. Rockville (MD): Agency for Healthcare Research and Quality (US).Google Scholar
García-Escalera, J., Chorot, P., Valiente, R. M., Reales, J. M., & Sandín, B. (2016). Efficacy of transdiagnostic cognitive-behavioral therapy for anxiety and depression in adults, children and adolescents: A meta-analysis. Revista de Psicopatología y Psicología Clínica, 21(3), 147–175. https://doi.org/10.5944/rppc.vol.21.num.3.2016.17811CrossRefGoogle Scholar
Gouvernement du Québec, (2016). Nomenclature des titres d’emploi, des libellés, des taux et des échelles de salaire du réseau de la santé et des services sociaux. Retrieved from: https://cpnsss.gouv.qc.ca/fileadmin/fichiers/Nomenclature/Nomenclature_v2016-06-07.pdfGoogle Scholar
Gratzer, D., & Goldbloom, D. (2016). Making evidence-based psychotherapy more accessible in Canada. Canadian Journal of Psychiatry, 61(10), 618–623. https://doi.org/10.1177/0706743716642416CrossRefGoogle ScholarPubMed
Griffiths, E., & Vadlamudi, N. (2016). Cadth's $50,000 cost-effectiveness threshold: Fact or fiction? Value in Health, 19(7), A488–A489. https://doi.org/10.1016/j.jval.2016.09.821CrossRefGoogle Scholar
Grochtdreis, T., Brettschneider, C., Bjerregaard, F., Bleich, C., Boczor, S., Härter, M., … König, H. H. (2019). Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT). European Psychiatry, 57, 10–18. https://doi.org/10.1016/j.eurpsy.2018.12.007CrossRefGoogle ScholarPubMed
Gulliver, A., Griffiths, K. M., & Christensen, H. (2010). Perceived barriers and facilitators to mental health help-seeking in young people: A systematic review. BMC Psychiatry, 10, 113. https://doi.org/10.1186/1471-244X-10-113CrossRefGoogle ScholarPubMed
Hakkaart-van Roijen, L., van Straten, A., Al, M., Rutten, F., & Donker, M. (2006). Cost-utility of brief psychological treatment for depression and anxiety. The British Journal of Psychiatry: The Journal of Mental Science, 188(4), 323–329. https://doi.org/10.1192/bjp.188.4.323CrossRefGoogle Scholar
Harvey, A. G., & Gumport, N. B. (2015). Evidence-based psychological treatments for mental disorders: Modifiable barriers to access and possible solutions. Behaviour Research and Therapy, 68, 1–12. https://doi.org/10.1016/j.brat.2015.02.004CrossRefGoogle ScholarPubMed
Health Quality Ontario. (2017). Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment. Ontario Health assessment series [Internet], 17(15), 1–167. Retrieved from: https://www.hqontario.ca/Evidence-to-Improve-Care/Journal-Ontario-Health-Technology-Assessment-SeriesGoogle Scholar
Hoch, J. S., Briggs, A. H., & Willan, A. R. (2002). Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11(5), 415–430. https://doi.org/10.1002/hec.678CrossRefGoogle Scholar
Hoch, J. S., Rockx, M. A., & Krahn, A. D. (2006). Using the net benefit regression framework to construct cost-effectiveness acceptability curves: An example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of “community acquired” syncope. BMC Health Services Research, 6, 68. https://doi.org/10.1186/1472-6963-6-68CrossRefGoogle ScholarPubMed
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2014). Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: A meta-analysis. Journal of Consulting and Clinical Psychology, 82(3), 375–391. https://doi.org/10.1037/a0035491CrossRefGoogle ScholarPubMed
Honaker, J., King, G., & Blackwell, M. (2019). Amelia II: A program for missing data. R package version 1.7.6. Retrieved from https://cran.r-project.org/web/packages/Amelia/vignettes/amelia.pdfGoogle Scholar
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., … ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. (2013). Consolidated health economic evaluation reporting standards (CHEERS) – explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value in Health, 6(2), 231–250. https://doi.org/10.1016/j.jval.2013.02.002CrossRefGoogle Scholar
Institut de la statistique du Québec. (2017). Rémunération horaire moyenne des employés, résultats selon le sexe pour diverses caractéristiques de la main-d'oeuvre de l'emploi et du milieu de travail, Québec, Ontario et Canada. Retrieved November 8, 2017, from Statistique Canada, Enquête sur la population active, 2016, adapté par l'Institut de la statistique du Québec (ISQ) website http://www.bdso.gouv.qc.ca/pls/ken/ken213_afich_tabl.page_tabl?p_iden_tran=REPERLFBVLS1998126029709Zv9)J&p_lang=1&p_m_o=ISQ&p_id_ss_domn=1096&p_id_raprt=2769Google Scholar
Jain, G., Roy, A., Harikrishnan, V., Yu, S., Dabbous, O., & Lawrence, C. (2013). Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: Results from a survey of full-time employees in the United States. Journal of Occupational and Environmental Medicine, 55(3), 252–258. https://doi.org/10.1097/JOM.0b013e31828349c9CrossRefGoogle ScholarPubMed
Joesch, J. M., Sherbourne, C. D., Sullivan, G., Stein, M. B., Craske, M. G., & Roy-Byrne, P. (2012). Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychological Medicine, 42(9), 1937–1948. https://doi.org/10.1017/S0033291711002893CrossRefGoogle ScholarPubMed
Katon, W., Russo, J., Sherbourne, C., Stein, M. B., Craske, M., Fan, M.-Y., & Roy-Byrne, P. (2006). Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychological Medicine, 36(3), 353–363. https://doi.org/10.1017/S0033291705006896CrossRefGoogle ScholarPubMed
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., & Van Ameringen, M. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14(Suppl 1), S1. https://doi.org/10.1186/1471-244X-14-S1-S1CrossRefGoogle ScholarPubMed
Keetharuth, A. D., Brazier, J. E., Connell, J., Bjorner, J. B., Carlton, J., Buck, E. T., … Barkham, M. (2018). Recovering Quality of Life (ReQoL): A new generic self-reported outcome measure for use with people experiencing mental health difficulties. British Journal of Psychiatry, 212(1), 42–49. https://doi.org/10.1192/bjp.2017.10CrossRefGoogle ScholarPubMed
Keetharuth, A. D., Rowen, D., Bjorner, J. B., & Brazier, J. (2021). Estimating a preference-based index for mental health from the recovering quality of life measure: Valuation of recovering quality of life utility index. Value in Health, 24(2), 281–290. https://doi.org/10.1016/j.jval.2020.10.012CrossRefGoogle ScholarPubMed
Kessler, R. C., Ames, M., Hymel, P. A., Loeppke, R., McKenas, D. K., Richling, D. E., … Ustun, T. B. (2004). Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. Journal of Occupational and Environmental Medicine, 46(6 Suppl.), 23–37. https://doi.org/10.1097/01.jom.0000126683.75201.c5CrossRefGoogle ScholarPubMed
Kessler, R. C., Barber, C., Beck, A., Berglund, P., Cleary, P. D., McKenas, D., … Wang, P. (2003). The World Health Organization Health and Work Performance Questionnaire (HPQ). Journal of Occupational and Environmental Medicine, 45(2), 156–174. https://doi.org/10.1097/01.jom.0000052967.43131.51CrossRefGoogle ScholarPubMed
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62(6), 593–602. https://doi.org/10.1001/archpsyc.62.6.593CrossRefGoogle ScholarPubMed
Kim, D. D., Silver, M. C., Kunst, N., Cohen, J. T., Ollendorf, D. A., & Neumann, P. J. (2020). Perspective and costing in cost-effectiveness analysis, 1974–2018. PharmacoEconomics 38:10, 1135–1145. https://doi.org/10.1007/S40273-020-00942-2CrossRefGoogle ScholarPubMed
Konnopka, A., & König, H. (2020). Economic burden of anxiety disorders: A systematic review and meta-analysis. PharmacoEconomics, 38, 25–37. https://doi.org/10.1007/s40273-019-00849-7CrossRefGoogle ScholarPubMed
Koopmanschap, M. A., Rutten, F. F., van Ineveld, M. B., & van Roijen, L. (1995). The friction cost method for measuring indirect costs of disease. Journal of Health Economics, 14, 171–189. https://doi.org/10.1016/0167-6296(94)00044-5CrossRefGoogle ScholarPubMed
Lave, J. R., Frank, R. G., Schulberg, H. C., & Kamlet, M. S. (1998). Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry, 55, 645–651. https://doi.org/10.1001/archpsyc.55.7.645CrossRefGoogle ScholarPubMed
McClure, N. S., Sayah, F. A., Xie, F., Luo, N., & Johnson, J. A. (2017). Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value in Health, 20(4), 644–650. https://doi.org/10.1016/j.jval.2016.11.015CrossRefGoogle ScholarPubMed
Mental Health Commission of Canada. (2012). Changing directions, changing lives: The mental health strategy for Canada.. Calgary, AB: Author.Google Scholar
Mental Health Commission of Canada. (2017). Strengthening the case for investing in Canada's mental health system: economic considerations. Retrieved from: https://www.mentalhealthcommission.ca/wp-content/uploads/drupal/2017-03/case_for_investment_eng.pdfGoogle Scholar
Ministère de la Santé et des Services sociaux. (2017a). AS-471 – Rapports financiers annuels des établissements. Retrieved from https://www.donneesquebec.ca/recherche/fr/dataset/as-471-rapports-financiers-annuels-des-etablissements/resource/380f531c-7066-4d89-a873-9470e9ed0558Google Scholar
Ministère de la Santé et des Services sociaux. (2017b). Rapports statistiques annuels des CH, CHSLD et CLSC 2016-2017 [Annual statistical reports of the CH, CHSLD and CLSC 2016-2017]. Retrieved from https://publications.msss.gouv.qc.ca/msss/document-001972/Google Scholar
Mojtabai, R. (2005). Trends in contacts with mental health professionals and cost barriers to mental health care among adults with significant psychological distress in the United States: 1997–2002. American Journal of Public Health, 95(11), 2009–2014. https://doi.org/10.2105/AJPH.2003.037630CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence. (2011).Common mental health problems: identification and pathways to care [NICE Clinical Guideline No. 123]. https://www.nice.org.uk/guidance/cg123Google Scholar
Neumann, P. J., & Cohen, J. T. (2018). QALYS in 2018-advantages and concerns. JAMA – Journal of the American Medical Association, 319(24), 2473–2474. https://doi.org/10.1001/jama.2018.6072CrossRefGoogle ScholarPubMed
Newby, J. M., Twomey, C., Yuan Li, S. S., & Andrews, G. (2016). Transdiagnostic computerised cognitive behavioural therapy for depression and anxiety: A systematic review and meta-analysis. Journal of Affective Disorders, 199, 30–41. https://doi.org/10.1016/j.jad.2016.03.018CrossRefGoogle ScholarPubMed
Norton, P. J. (2012). Group cognitive-behavioral therapy of anxiety: A transdiagnostic treatment manual. New York: The Guilford Press.Google Scholar
Norton, P. J., & Roberge, P. (2017). Transdiagnostic therapy. Psychiatric Clinics of North America, 40, 675–687. https://doi.org/10.1016/j.psc.2017.08.003CrossRefGoogle ScholarPubMed
Organisation for Economic Co-operation and Development. (2021). Purchasing power parities (PPP) (indicator). Retrieved September 20, 2021, from https://data.oecd.org/conversion/purchasing-power-parities-ppp.htmGoogle Scholar
Paton, N. I., Stöhr, W., Oddershede, L., Arenas-Pinto, A., Walker, S, Sculpher, M, … Dunn, D. T.. (2016). The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technology Assessment, 20(21). https://doi.org/10.3310/hta20210CrossRefGoogle Scholar
Payakachat, N., Ali, M. M., & Tilford, J. M. (2015). Can The EQ-5D detect meaningful change? A systematic review. PharmacoEconomics, 33(11), 1137–1154. https://doi.org/10.1007/s40273-015-0295-6CrossRefGoogle ScholarPubMed
Pearl, S. B., & Norton, P. J. (2017). Transdiagnostic versus diagnosis specific cognitive behavioural therapies for anxiety: A meta-analysis. Journal of Anxiety Disorders, 46, 11–24. https://doi.org/10.1016/j.janxdis.2016.07.004CrossRefGoogle ScholarPubMed
Perreault, M., Lafortune, D., Laverdure, A., Chartier-Otis, M., Bélanger, C., Marchand, A., … Milton, D. (2013). Barriers to treatment access reported by people with anxiety disorders. Canadian Journal of Psychiatry, 58(5), 300–305. https://doi.org/10.1177/070674371305800508CrossRefGoogle ScholarPubMed
Régie de l'assurance maladie du Québec. (2016a). Manuel des médecins omnipraticiens (n 100) [General practitioners’ manual (n 100)]. Retrieved July 26, 2020, from https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/100-facturation-omnipraticiens/000_complet_acte_omni.pdfGoogle Scholar
Régie de l'assurance maladie du Québec. (2016b). Manuel des médecins spécialistes (MAJ89) [Specialist physicians’ manual (MAJ89)]. Retrieved July 26, 2020, from http://collections.banq.qc.ca/ark:/52327/bs2580637Google Scholar
Régie de l'assurance maladie du Québec. (2018). Liste des médicaments. Retrieved July 27, 2020, from https://www.ramq.gouv.qc.ca/fr/media/6056Google Scholar
Reinholt, N., & Krogh, J. (2014). Efficacy of transdiagnostic cognitive behaviour therapy for anxiety disorders: A systematic review and meta-analysis of published outcome studies. Cognitive Behaviour Therapy, 43(3), 171–184. https://doi.org/10.1080/16506073.2014.897367CrossRefGoogle ScholarPubMed
Rens, E., Dom, G., Remmen, R., Michielsen, J., & Van Den Broeck, K. (2020). Unmet mental health needs in the general population: Perspectives of Belgian health and social care professionals. International Journal for Equity in Health, 19, 169. https://doi.org/10.1186/s12939-020-01287-0CrossRefGoogle ScholarPubMed
Richardson, J., Iezzi, A., Khan, M. A., & Maxwell, A. (2014a). Validity and reliability of the assessment of quality of life (AQoL)-8D multi-attribute utility instrument. Patient, 7, 85–96. https://doi.org/10.1007/s40271-013-0036-xCrossRefGoogle ScholarPubMed
Richardson, J., Sinha, K., Iezzi, A., & Khan, M. A. (2014b). Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(8), 2395–2404. https://doi.org/10.1007/s11136-014-0686-8CrossRefGoogle ScholarPubMed
Ridic, G., Gleason, S., & Ridic, O. (2012). Comparisons of Health Care Systems in the United States, Germany and Canada. Materia Socio Medica, 24(2), 112. https://doi.org/10.5455/msm.2012.24.112-120CrossRefGoogle ScholarPubMed
Roberge, P., Marchand, A., Reinharz, D., & Savard, P. (2008). Cognitive-behavioral treatment for panic disorder with agoraphobia: A randomized, controlled trial and cost-effectiveness analysis. Behavior Modification, 32(3), 333–351. https://doi.org/10.1177/0145445507309025CrossRefGoogle ScholarPubMed
Roberge, P., Provencher, M. D., Gaboury, I., Vasiliadis, H.-M., Benoit, A., Carrier, N., … Norton, P. J. (2022). Group transdiagnostic cognitive-behaviour therapy for anxiety disorders: A pragmatic randomized clinical trial. Psychological Medicine, 52(13), 2460–2470. https://doi.org/10.1017/S0033291720004316CrossRefGoogle Scholar
Roberge, P., Provencher, M. D., Gosselin, P., Vasiliadis, H.-M., Gaboury, I., Benoît, A., … Norton, P. J. (2018). A pragmatic randomized controlled trial of group transdiagnostic cognitive – behaviour therapy for anxiety disorders in primary care: Study protocol. BMC Psychiatry, 18, 320. https://doi.org/doi:10.1186/s12888-018-1898-1CrossRefGoogle ScholarPubMed
Scuffham, P., Vecchio, N., & Whiteford, H. (2014). Exploring the validity of HPQ-based presenteeism measures to estimate productivity losses in the health and education sectors. Medical Decision Making, 34(1), 127–137. https://doi.org/10.1177/0272989X13497996CrossRefGoogle ScholarPubMed
Sharma, D., Aggarwal, A. K., Downey, L. E., & Prinja, S. (2021). National healthcare economic evaluation guidelines: A cross-country comparison. PharmacoEconomics – Open, 5, 349–364. https://doi.org/10.1007/S41669-020-00250-7CrossRefGoogle ScholarPubMed
Simons, C. J. P., Drukker, M., Evers, S., van Mastrigt, G. A. P. G., Höhn, P., Kramer, I., … Wichers, M. (2017). Economic evaluation of an experience sampling method intervention in depression compared with treatment as usual using data from a randomized controlled trial. BMC Psychiatry, 17, 415. https://doi.org/10.1186/S12888-017-1577-7CrossRefGoogle ScholarPubMed
Statistics Canada. (2020). Consumer Price Index, monthly, not seasonally adjusted. Retrieved June 29, 2020, from https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000401#timeframe.Google Scholar
Sweeney, A., Clement, S., Gribble, K., Jackson, E., Carr, S., Catty, J., & Gillard, S. (2019). A systematic review of qualitative studies of adults’ experiences of being assessed for psychological therapies. Health Expectations, 22, 133–148. https://doi.org/10.1111/hex.12844CrossRefGoogle ScholarPubMed
Tang, K. (2015). Estimating productivity costs in health economic evaluations: A review of instruments and psychometric evidence. PharmacoEconomics, 33(1), 31–48.CrossRefGoogle ScholarPubMed
van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. H. (1994). Costs, effects and C/E-ratios alongside a clinical trial. Health Economics, 3(5), 309–319. https://doi.org/10.1002/hec.4730030505CrossRefGoogle Scholar
van Nieuwenhuyse, H., & Dumas, M.-E. (2012). Rapport d'appréciation de la performance du système de santé et de services sociaux [Report on the performance of the health and social services system]. Commissaire à la santé et au bien-être du Québec. Retrieved from: https://www.csbe.gouv.qc.ca/fileadmin/www/2012/SanteMentale/CSBE_Rapport_Appreciation_SanteMentale_2012.pdfGoogle Scholar
Vannoy, S. D., Arean, P., & Unützer, J. (2010). Advantages of using estimated depression-free days for evaluating treatment efficacy. Psychiatric Services, 61(2), 160–163. https://doi.org/10.1176/ps.2010.61.2.160CrossRefGoogle ScholarPubMed
Vasiliadis, H.-M., & Dezetter, A. (2017). Les programmes de prise en charge financière des psychothérapies en Australie et en Angleterre Les programmes de prise en charge financière des psychothérapies en Australie et en Angleterre [Financial assistance programs for psychotherapy in Australia…]. Santé Mentale Au Québec, 40(4), 101–118.CrossRefGoogle Scholar
Walker, E. R., Cummings, J. R., Hockenberry, J. M., & Druss, B. G. (2015). Insurance status, use of mental health services, and unmet need for mental health care in the United States. Psychiatric Services, 66(6), 578–584. https://doi.org/10.1176/appi.ps.201400248CrossRefGoogle ScholarPubMed
Xie, F., Pullenayegum, E., Gaebel, K., Bansback, N., Bryan, S., Ohinmaa, A., … Johnson, J. A. (2016). A time trade-off-derived value set of the EQ-5D-5L for Canada. Medical Care, 54(1), 98–105. https://doi.org/10.1097/MLR.0000000000000447CrossRefGoogle ScholarPubMed
Yuasa, A., Yonemoto, N., LoPresti, M., & Ikeda, S. (2020). Use of productivity loss/gain in cost-effectiveness analyses for drugs: A systematic review. PharmacoEconomics 39, 81–97. https://doi.org/10.1007/S40273-020-00986-4CrossRefGoogle ScholarPubMed
Supplementary material: File

Chapdelaine et al. supplementary material

Chapdelaine et al. supplementary material 1

Download Chapdelaine et al. supplementary material(File)
File 41.7 KB
Supplementary material: File

Chapdelaine et al. supplementary material

Chapdelaine et al. supplementary material 2

Download Chapdelaine et al. supplementary material(File)
File 511.2 KB